RxDoctor Payments Data

Jospeh Akamah, MD

Interventional Cardiology · Nashville, TNNPI 1598822967

Payments from drug & device makers

$6,552in general payments, 2019–2025

Across 66 payments — averaging $99.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$2K
  • Medtronic$1K
  • Boston Scientific$1K
  • CMS Imaging, Inc.$1K
  • Novartis$197
  • AstraZeneca$160
  • plus $536 from 14 others

What the payments were for

  • Travel & lodging$3,41552%
  • Food & beverage$3,13748%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,552 in reported general payments places this provider in the 35th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$61,705
Medicare patients
363
Services billed
839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$77,103
FarxigaDapagliflozin Propanediol20$28,913
JardianceEmpagliflozin29$27,079
EntrestoSacubitril/Valsartan19$19,599
Atorvastatin Calcium113$1,142
Metoprolol Succinate71$905
ClopidogrelClopidogrel Bisulfate68$767
Losartan Potassium63$713
Nitroglycerin36$683
Carvedilol90$640
Albuterol Sulfate HfaAlbuterol Sulfate17$632
Isosorbide Mononitrate ErIsosorbide Mononitrate38$621
Furosemide96$576
Rosuvastatin Calcium34$440
Lisinopril59$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$77,10369 claims
AstraZenecaFarxiga$160$28,91320 claims
Boehringer IngelheimJardiance$18$27,07929 claims
NovartisEntresto$197$19,59919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →